2 completed. 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 2 | Completed 2 |
Follow Human Papillomavirus: new trials by email Literature Review of Human Papillomavirus trials Research Report on Human Papillomavirus
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Immunogenicity and Tolerability of V503 Versus GARDASIL (V503-009) V503, GARDASIL - Human Papillomavirus | Phase 3 | Completed | Merck Sharp & Dohme LLC | 600 | 2011-02-23 | 2018-12-14 |
| Immunogenicity of Gardasil and Twinrix and the Effect of a Dose of Gardasil or Cervarix Given 42 Months Later. Gardasil vaccine, Immunogenicity, Booster dose., Cervarix Vaccine, Immunogenicity, Booster Dose. - Human Papillomavirus | Phase 3 | Completed | Laval University | 418 | 2008-09-01 | 2020-03-05 |
Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 (1) · Papillomavirus Vaccines (1)
Laval University (1) · Merck Sharp & Dohme LLC (1)
Canada (1)